Moleboheng Emily Motseki

Dr. Moleboheng Emily Motseki


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023
Verified
Book Chapter
Open access
PDF file
MMMoleboheng Emily Motseki
Moleboheng Emily Motseki
PMPolo-Ma-Abiele Hildah Mfengwana
Polo-Ma-Abiele Hildah Mfengwana
The first case of coronavirus disease of 2019 (COVID-19) in South Africa (SA) was first reported at the beginning of March 2022, and then further spread from Gauteng, Western Cape, and KwaZulu Natal to the rest of the provinces. It is caused by severe acute respiratory syndrome coronavirus 2. In SA, COVID-19 is less prevalent in children less than 18 years. Only a few studies describe the epidemiology, risk factors, and clinical manifestation of COVID-19 among children in SA in comparison to other countries including China, North America, and Europe. South African children are affected by conditions including poverty, tuberculosis, and human immunodeficiency virus which predispose them to COVID-19. Overcrowding and limited healthcare facilities and resources also complicated the diagnosis and clinical and pharmacological management of COVID-19 in SA. The current review discusses the prevalence, risk factors, and management of COVID-19 in South African children in comparison to other continents in the world.

14 February 2024
Verified
Book Chapter
Open access
PDF file
MMMoleboheng Emily Motseki
Moleboheng Emily Motseki
SMSamson Sitheni Mashele
Samson Sitheni Mashele
PMPolo-Ma-Abiele Hildah Mfengwana
Polo-Ma-Abiele Hildah Mfengwana
Fungal infections are still most prevalent in the South African population. Fungal respiratory infections and diseases are the cause of severe clinical challenges and mortality in patients with compromised immune systems. Clinical signs of coronavirus disease of 2019 (COVID-19) such as lung injury, hyperglycemia due to diabetes, host iron and zinc depletion, hypoxia, immunosuppression, steroid therapy, and long-term hospitalization predispose patients to opportunistic fungal infections. Fungal pathogens, including Cryptococcus, Aspergillus, and Candida species, cause coinfections in patients infected with (COVID-19), and this has a negative impact on the patients’ pharmacological management goals. Cryptococcus, Aspergillus, and Candida species cause respiratory infections and illnesses including pneumonia, pulmonary aspergillosis, pulmonary candidiasis, and pulmonary cryptococcosis. South African traditional medicinal plants have been used in the treatment of respiratory symptoms and diseases caused by these fungal pathogens. Medicinal plants contain secondary metabolites possessing antifungal activity against Cryptococcus, Aspergillus, and Candida species. Moreover, medicinal plants are cheaper and easily accessible and are believed to be safe. This review documents the use of South African traditional medicinal plants including Artemisia absinthium, Artemisia afra, Dicoma anomala, Felicia species, Mentha species, Ruta graveolens, and Seasia erosa in the treatment of fungal infections and diseases caused by these pathogens.